Hefei Yingtai Pharmaceutical Co Ltd.

Primary objective: To evaluate the bioequivalence of ziprasidone hydrochloride capsules (trade name: Zoladin) licensed by Pfizer OFG Germany GmbH as the reference formulation and ziprasidone hydrochloride capsules licensed by Hefei Yingtai Pharmaceutical Co., Ltd. as the test formulation in humans under fasting conditions through a single-center, randomized, open-label, single-dose, two-period, double-crossover clinical trial. Secondary objective: To observe the safety of the test and reference formulations in healthy participants in China.

Primary objective: To evaluate the bioequivalence of the test formulation mesalazine extended-release granules (1g, manufacturer: Hefei Yingtai Pharmaceutical Co., Ltd.) and the reference formulation mesalazine extended-release granules (1g, calculated as mesalazine (C7H7NO3)), manufacturer: Ferring S.A.S., trade name: Pentasa®), in healthy participants after oral administration under fasting and postprandial conditions, using pharmacokinetic parameters as the primary endpoint. Secondary objectives: To observe the safety of the test and reference formulations in healthy participants; to evaluate the palatability of the test and reference formulations.

Primary Objective: To evaluate the pharmacokinetic characteristics of a single oral dose of the test formulation (T) and the reference formulation (R) of iripeprazole orally disintegrating tablets (Trexulti®) manufactured by Hefei Yingtai Pharmaceutical Co., Ltd., in healthy participants under fasting and postprandial conditions, and to assess the bioequivalence of the two formulations in humans. Secondary Objective: To investigate the safety of the test and reference formulations after oral administration in healthy participants. To evaluate the palatability of iripeprazole orally disintegrating tablets in healthy Chinese participants, providing a basis for understanding the taste of iripeprazole orally disintegrating tablets.